clinical trial · NCT07309445
A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States
Janssen Research & Development, LLC·—·recruiting·n = 150
Non-Muscle Invasive Bladder Neoplasms
brief summary
The purpose of this study is to assess how well TAR-200 works in real-word by measuring the time taken from the first TAR-200 insertion to worsening of cancer or until the signs and symptoms of cancer occur again (disease-free survival) in participants with non-muscle invasive bladder cancer (NMIBC; an early-stage bladder cancer that is limited to the inner lining of bladder).
started
Apr 30, 2026
primary completion
Mar 31, 2029
completion
Oct 31, 2029
last updated
Apr 13, 2026
official title
A Multicenter, Prospective, Longitudinal Study to Assess Real-World Use and Outcomes After the Launch of TAR-200 for NMIBC in the US
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol